Entrata files for proposed IPO

Entrata (ENT) filed for a proposed IPO on the NYSE. Goldman Sachs, J.P. Morgan, and Barclays will serve as lead underwriters. The filing marks a step toward the company's public debut.

Original reporting
Published Sep 1, 2026, 10:21 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 10:37 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefIPO
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ENT
Relevance
5/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

Low
01

Timing

today

Relevance 5/10Novelty 6/10Timing: today

Related articles

$ENTMedAI 8/10

Phased exit of Entain CEE - 20% divestment agreed

Entain said it agreed to sell a 20% interest in Entain Holdings (CEE) Ltd to joint venture partner EMMA Capital in a phased exit. The deal values Entain CEE at about €2.1bn (c.10x EBITDA) and provides ~€425m cash, including €395m on completion plus an early-2027 payment. Net proceeds will reduce debt; completion is expected in Q4 2026.

$SECZMed

Securitize Lists on NYSE and Tokenizes Its Own Stock on Day 1

Securitize (SECZ) began trading on the NYSE at $12.45, closing at $12.30. It also tokenized its stock on Solana and Avalanche, with $295M in tokenized shares at launch. The company aims to tokenize IPO allocations for crypto investors, targeting transactions within 3-6 months. Securitize reported $3.4B in tokenized assets and $19.5M in Q1 2026 revenue, up 39% YoY.

$SWMRHigh

Why SWMR Stock Soared Over 500% In Nasdaq Debut Today

Swarmer, Inc. (SWMR) shares surged 520% in its Nasdaq debut, closing at $31 after pricing its IPO at $5 per share, raising $15 million. The company, which develops drone software, plans to use proceeds for operations and expansion. Revenue was $309,920 in 2025, with a net loss of $8.5 million. CEO Alex Fink highlighted global demand driven by conflicts and the need for battlefield automation.

$ODTXHighAI 8/10

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Odyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.

$OWLMedAI 8/10

Blue Owl Plans Data Center REIT IPO with AI Boom

Blue Owl Capital plans to create a data center REIT and take it public, seeding it with $6.5B of its own assets. The company aims to raise funds through an IPO and additional share sales to expand its portfolio. Blue Owl's shares rose 1.2% on the news, despite a 21% decline this year. Global data center expenditure is projected to reach $1.2T by 2028, according to Bloomberg Intelligence.